/ /

  • linkedin
  • Increase Font
  • Sharebar

    Second blood-vessel-growth protein implicated in PDR


    “Acquiring aqueous fluid from patients is relatively straightforward and poses limited risks on patients, and although there is considerable overlap of VEGF levels in aqueous fluid of control patients, diabetic patients without diabetic retinopathy, and diabetics with no-proliferative diabetic retinopathy or PDR, ANGPTL4 levels were strongly predictive of the presence or absence of PDR,” the researchers wrote.

    “Although therapies targeting the potent angiogenic mediator vascular endothelial growth factor have been remarkably successful for the treatment of diabetic macular edema, this approach has not proven sufficient to prevent the development of retinal neovascularization, implicating additional angiogenic factor(s) in PDR pathogenesis,” the researchers concluded. “We demonstrate here that angiopoietin-like 4 is a potent angiogenic mediator with markedly increased expression in the eyes of PDR patients. Our studies identify a novel therapeutic target for the treatment of ocular neovascular disease and may have broad implications for the treatment of other diseases dependent on pathologic angiogenesis.” 

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results